A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2016
At a glance
- Drugs Cobimetinib (Primary) ; Ipatasertib (Primary)
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 25 Mar 2016 no of arms changed from 2 to 3 as per ClinicalTrials.gov record.
- 01 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History